Tag archive for ‘Antares response to Complete Response Letter’
Antares’ Response to Complete Response Letter on Xyosted is in Line with My Expectations (ATRS, Buy, $2.05)
Antares Pharma announced on December 21st that it had submitted a request to the FDA for a type A meeting in response to the CRL that it received in October on Xyosted. This action and timing is in line with what I have been expecting. See my note of November 9, 2017: My Hypothesis on […]